Real-World Determinants of Treatment Selection in Frontline Chronic Lymphocytic Leukemia: The FIRST-CLL Study. (PubMed, Hematol Oncol) - Sep 17, 2026 - "Overall, 116 patients (41%) received continuous Bruton tyrosine kinase inhibitors (BTKi), 114 (40%) ibrutinib plus venetoclax (IV), and 55 (19%) venetoclax plus obinutuzumab (VO). Comorbidity burden additionally guided BTKi prescription, whereas molecular features were more relevant in the selection of fixed-duration regimens. This study offers a real-world quantitative assessment of treatment decision drivers in frontline CLL, offering a data-driven framework to interpret clinical decision-making."
Journal • Real-world evidence • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • Small Lymphocytic Lymphoma • IGH • TP53
|
|
Alessandro Bosi; Andrea Ferrario; Andrea Galitzia; Anna Maria Frustaci; Benedetto Bruno; Candida Vitale; Chiara Salvetti; Daniela Gottardi; Elia Boccellato; Erika Fioribello; Francesca Perutelli; Francesca Romana Mauro; Gianluca Gaidano; Ilaria Piras; Jacopo Olivieri; Marina Deodato; Marta Coscia; Martina Bullo; Matteo Arata; Maura Nicolosi; Michela Schirru; Michele Merli; Myriam Foglietta; Raffaella Pasquale; Riccardo Moia; Roberta Murru; Roberto Freilone; Sara Pepe
|